- •MS can impair quality of life and work productivity and increase resource use.
- •Increasing perceived severity of MS can contribute to these impairments.
- •Yet, the mild-to-moderate-to-severe transition may be nonlinear.
- •Greater health outcomes impairments may occur with mild-to-moderate shifts in disability.
- •Findings show increasing disease severity is associated with worse health outcomes.
Individuals with multiple sclerosis (MS) experience diminished health outcomes. However, little is known about how these outcomes differ according to disease severity. The aim of this study is to compare health-related quality of life (HRQoL), work productivity, activity impairment, and resource use between MS patients and controls, as well as across MS patients with varying self-reported disease severity.
Data were analyzed from respondents reporting an MS diagnosis (n=536) and controls (n=74,451) in the U.S. 2009 National Health and Wellness Survey (administered online to a nationally representative adult population). Differences were assessed between those with and without MS, and across three MS severity groups: mild (38.4%), moderate (50%), and severe (11.6%).
MS patients vs. controls experienced significantly more activity impairment, decreased work productivity, increased healthcare utilization, and lower HRQoL (all p<0.001). Increasing MS severity was associated with greater activity impairment, lower work productivity, increased healthcare utilization, and lower HRQoL. More significant impairments emerged between individuals who perceived their disease severity as mild vs. moderate than moderate vs. severe.
MS patients reported greater impairment than controls, and impairment increased with disease severity (especially from mild to moderate). These findings show that increasing MS disease severity is associated with worse health outcomes.
Abbreviations:BMI (Body Mass Index), CCI (Charlson Comorbidity Index), DMD (Disease Modifying Drug), EDSS (Expanded Disability Status Scale), ER (Emergency Room), NHWS (National Health and Wellness Survey), HRQoL (Health-Related Quality of Life), MCS (Mental Component Summary), MS (Multiple Sclerosis), PCS (Physical Component Summary), PROs (Patient-Reported Outcomes), SF-6D (Short Form 6D), SF-12v2 (The Medical Outcomes Study 12-Item Short Form Survey Instrument), U.S. (United States), WPAI (Work Productivity and Activity Impairment Questionnaire)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Clinical outcome measures for research in multiple sclerosis.Journal of Neuro-Ophthalmology. 2001; 21: 296-301
- The estimation of a preference-based measure of health from the SF-36.Journal of Health Economics. 2002; 21: 271-292
- The estimation of a preference-based measure of health from the SF-12.Medical Care. 2004; 42: 851-859
- Association of insomnia with quality of life, work productivity, and activity impairment.Quality of Life Research. 2009; 18: 415-422
- Absenteeism and health-benefit costs among employees with MS.Current Medical Research and Opinion. 2009; 25: 1469-1476
- A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.Journal of Chronic Diseases. 1987; 40: 373-383
- Depression and anxiety in a Portuguese MS population: associations with physical disability and severity of disease.Journal of the Neurological Sciences. 2011; 306: 66-70
- The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities.Journal of Medical Economics. 2011; 14: 253-261
- An examination of suicidal intent in patients with multiple sclerosis.Neurology. 2002; 59: 674-678
- Direct and indirect costs and potential cost savings of laparoscopic adjustable gastric banding among obese patients with diabetes.Journal of Occupational and Environmental Medicine. 2011; 53: 1025-1029
- Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use.Calcified Tissue International. 1997; 61: 129-133
- Quality of life in patients with multiple sclerosis: the impact of depression, fatigue, and disability.International Journal of Rehabilitation Research. 2011; 34: 290-298
- Patient reported outcomes in benign multiple sclerosis.Multiple Sclerosis. 2011; 17: 876-884
- Validity of patient-derived disability and clinical data in multiple sclerosis.Multiple Sclerosis. 2010; 16: 472-479
- The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.Pharmacoeconomics. 2009; 27: 681-691
- The socioeconomic consequences of multiple sclerosis: a controlled national study.European Neuropsychopharmacology. 2012; 22: 36-43
- Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States.Neurology. 2006; 66: 1696-1702
- Socioeconomic trends in hospitalization for multiple sclerosis.Neuroepidemiology. 2010; 35: 93-99
- Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue, and sleep quality.Acta Neurologica Scandinavica. 2004; 110: 6-13
- Depression in multiple sclerosis as a function of length and severity of illness, age, remissions, and perceived social support.Jouirnal of Clinical Psychology. 1984; 40: 1028-1033
- Fatigue and depression in multiple sclerosis: correlation with quality of life.Archives of Biological Sciences. 2011; 63: 617-622
- Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life.Neurology. 2010; 74: S24-S35
- Economic burden of multiple sclerosis: a systematic review of the literature.Pharmacoeconomics. 2010; 28: 363-379
- Nutrition and diet in the clinical management of multiple sclerosis.Journal of Human Nutrition and Dietetics. 2001; 14: 349-357
- Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study.Archives of Neurology. 2004; 61: 679-686
- Prevalence, expenditures, utilization, and payment for persons with MS in insured populations.Neurology. 2002; 58: 37-43
- Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.Journal of Managed Care Pharmacy. 2007; 13: 44-52
- The validity and reproducibility of a work productivity and activity impairment instrument.Pharmacoeconomics. 1993; 4: 353-365
- Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial.Current Medical Research and Opinion. 2009; 25: 1121-1130
- Life at work after multiple sclerosis.Journal of Vocational Rehabilitation. 2004; 20: 153-154
- Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment.CNS Drugs. 2008; 22: 827-839
- Illness perception and health-related quality of life in multiple sclerosis.Acta Neurologica Scandinavica. 2007; 116: 293-299
Stüve O, Oksenberg J. Multiple sclerosis overview. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, 1993-2013; 2006 Jan 2010 [updated 2010 May 11]
- Disability progression in multiple sclerosis is slower than previously reported.Neurology. 2006; 66: 172-177
- How to score version 2 of the SF-12® health survey (with a supplemental documenting version 1).QualityMetric Incorporated, Lincoln, RI2002
- Case-finding instruments for depression. Two questions are as good as many.Journal of General Internal Medicine. 1997; 12: 439-445
- Smoking: effects on multiple sclerosis susceptibility and disease progression.Therapeutic Advances in Neurological Disorders. 2012; 5: 13-22
- Contribution of intangible costs to the economic burden of multiple sclerosis.Journal of Medical Economics. 2010; 13: 626-632
Published online: July 01, 2013
Accepted: June 2, 2013
Received in revised form: May 7, 2013
Received: October 29, 2012
© 2013 Elsevier B.V. Published by Elsevier Inc. All rights reserved.